期刊论文

中文

中国感染控制杂志

1671-9638

2009

8

3

160-163

10.3969/j.issn.1671-9638.2009.03.004

湖南省自然科学联合基金项目（07JJ6165）；

本校为第一机构

目的 探讨乙型肝炎病毒(HBV)基因型与核苷(酸)类似物耐药变异的关系.方法 湖南省衡阳地区122例慢性乙型肝炎患者接受拉米夫定治疗(100 mg/d)48～96周,发生耐药变异者改用阿德福韦酯治疗(10 mg/d)96周.采用直接测序法进行HBV基因分型,同时检测拉米夫定、阿德福韦酯和恩替卡韦耐药变异位点.结果 122例慢性乙型肝炎患者中,B基因型86例(70.49%),C基因型24例(19.67%),未分型12例(9.84%).42例检出拉米夫定变异株,其中B基因型32例,C基因型10例,B、C基因型拉米夫定耐药变异率分别为37.21%(32/86)和41.67%(10/24),差异无显著性(X2=0.16,P=0.69);42例经阿德福韦酯治疗48周和96周的变异发生率分别为0.00%(0...

Objective To study the relationship between HBV genotypes and nucieolide analogues drug-resistance mutations. Methods One hundred and twenty-two patients with chronic hepatitis B were treated with lamivudine 100mg/d for 48-96 weeks, patients who developed lamivudine-resistance mutations used adefovir dipivoxil 10mg/d for 96 weeks instead of lamivudine. HBV genotypes, lamivudine, adefovir dipivoxil and entecavir resistance mutations were determined by DNA sequencing. Results Among 122 cases, 86 （70. 490/6o） were genotype B, 24 （19. 67%） were...